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Two human parvoviruses were recently discovered by metagenomics in Africa, bufavirus (BuV) in 2012 
and tusavirus (TuV) in 2014. These viruses have been studied exclusively by PCR in stool and detected 
only in patients with diarrhoea, although at low prevalence. Three genotypes of BuV have been 
identified. We detected, by in-house EIA, BuV1-3 IgG antibodies in 7/228 children (3.1%) and 10/180 
adults (5.6%), whereas TuV IgG was found in one child (0.4%). All children and 91% of the adults were 
Finnish, yet interestingly 3/6 adults of Indian origin were BuV-IgG positive. By competition EIA, no 
cross-reactivity between the BuVs was detected, indicating that the BuV genotypes represent distinct 
serotypes. Furthermore, we analysed by BuV qPCR stool and nasal swab samples from 955 children with 
gastroenteritis, respiratory illness, or both, and found BuV DNA in three stools (0.3%) and for the first 
time in a nasal swab (0.1%). This is the first study documenting the presence of BuV and TuV antibodies 
in humans. Although the seroprevalences of both viruses were low in Finland, our results indicate that 
BuV infections might be widespread in Asia. The BuV-specific humoral immune responses appeared to 
be strong and long-lasting, pointing to systemic infection in humans.
The development of modern deep sequencing and metagenomic techniques have facilitated recent discoveries of 
several novel parvoviruses in various animal species, including humans. Of the novel putative human parvovi-
ruses, bufavirus (BuV) and tusavirus (TuV) are among the newest: both of these viruses were originally discov-
ered in the stools of diarrheic children in Africa - BuV in 2012 in Burkina Faso and TuV in 2014 in Tunisia1,2.
Parvoviruses are small, non-enveloped viruses with a single-stranded DNA genome of 4–6 kb, encoding only a 
few proteins. The classification of parvoviruses is currently based on the non-structural protein (NS1) sequence3, 
and both BuV and TuV are classified in the Protoparvovirus genus in the Parvoviridae family. Human bufaviruses 
are conserved in the NS1 protein (94–96% similarity at the amino acid (aa) level)4, and thus belong to one species, 
Primate protoparvovirus 13. However, the BuV capsid proteins VP1 and VP2 share only 71–78% and 64–73% sim-
ilarities at the aa level, respectively, generating three genotypes4,5. Tusavirus on the other hand has been described 
only in one child2, although partial TuV-like sequences have been detected in fur seals in Brazil6.
To date, bufavirus has been searched for exclusively in stool samples, and it has been detected in diarrheal 
stools of children and adults in Africa, Europe and Asia, including Burkina Faso, Tunisia, Bhutan, Finland, the 
Netherlands, Thailand, Turkey and China1,5,7–11. The prevalence in patients has been low, 0.3% to 4%, and although 
in three publications stool samples from non-diarrheic patients or healthy subjects were shown to be BuV-DNA 
negative9–11, the etiological role of the virus in diarrhoea or in other human diseases remains uncertain.
BuV-like viruses have been found in wild and captive non-human primates as well as in swine, shrews, rats, 
bats and fur seals4,6,12–17. The detection of these viruses in sera of rhesus monkeys in the USA, and in the spleen of 
wild baboons and shrews in Zambia, suggests that BuV-like viruses may cause systemic infections12,13.
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We first analysed by quantitative PCR the presence of BuV DNA in stool and, for the first time, also in nasal 
swab samples from 955 children with symptoms of acute gastroenteritis, acute respiratory infection or both. The 
mere presence of viral DNA in stool or in other sample types does, however, not necessarily indicate a causal role 
to a disease, neither does the transient PCR positivity give a true picture of how common the virus is in the popu-
lation. In this study we therefore investigated the prevalence of BuV- and TuV-specific IgG antibodies, which can 
reveal prior virus encounters. We created virus-like particles (VLP) of the major VP2 capsid proteins of all three 
BuV genotypes and of TuV, applied them as antigens in IgG EIAs, and analysed 180 serum samples from healthy 
adults and 228 serum samples from the same paediatric cohort to assess the epidemiology of these viruses.
Results
Bufavirus DNA in nasal swab and stool samples in the paediatric cohort. BuV DNA was detected 
in 1/955 (0.1%) nasal swab and in 3/955 (0.3%) stools (Table 1). The results were confirmed by sequencing the 
qPCR amplicons. We were not able to amplify the VP region of the viral genome from these samples, possibly 
due to low quantity and/or limited sample volume; the genotypes therefore remained unknown. The viral loads 
of the samples were 2.1 × 102–1.6 × 103 copies/ml stool suspension and 4.6 × 103 copies/ml nasal swab medium 
(Table 1). All four BuV DNA-positive children had gastrointestinal symptoms, while all of the 545 non-diarrheic 
children were BuV-DNA negative. However, all four children had in stool also another virus known to cause 
gastroenteritis (Table 1). 
Bufavirus and tusavirus VP2 VLPs. The VP2 genes were cloned from the original BuV and TuV 
DNA-positive stool samples and used to create recombinant VP2 VLPs for BuV1, 2 and 3 as well as TuV. The 
four types of VLPs were expressed in insect cell cultures and purified by CsCl ultracentrifugation. SDS-gel elec-
trophoresis showed proteins of expected sizes, approximately 64 kDa for BuVs and 62 kDa for TuV, and electron 
microscopy disclosed parvovirus-like VLPs of ~25 nm in diameter (Fig. 1).
Bufavirus and tusavirus IgG in adults. Ten subjects (10/180, 5.6%) were BuV IgG seropositive: four sub-
jects for BuV1, five for BuV2 and one for all three bufaviruses (triple positive) (Tables 2 and 3, and Fig. 2). Three 
of the BuV1 seropositives and the triple seropositive showed very high OD values (OD 1.9–4.0, Table 2 and 
Fig. 2). None of the 180 adult sera were positive for TuV IgG. Although most of the adults were of Finnish descent 
(163/180, 90.6%), of the ten BuV IgG-positive subjects five were from the Middle-East, India or China, including 
all four with high OD values. They had moved to Finland as adults, and were 26 to 34 years of age at the time of 
No. Sample type
BuV DNA quantity (copies 
per ml supernatant) Age, gender Sampling date Symptoms Other pathogens found
1 Swab 4.6 × 103 20 months, M 27.3.2011 AGE + ARTI swab: neg* (stool: norovirus, HBoV2# serum: HBoV2#)
2 Stool 2.1 × 102 4 yrs 5 months, F 23.2.2010 AGE norovirus
3 Stool 8.5 × 102 23 months, F 6.3.2011 AGE rotavirus, HBoV2
4 Stool 1.6 × 103 10 months, F 9.1.2011 AGE + ARTI norovirus
Table 1.  Bufavirus DNA-positive children. *Only boca- and coronaviruses were tested from nasal swabs. #An 
acute bocavirus 2 (HBoV2) infection was diagnosed based on serology in this child18. The corresponding stool 
and serum samples of this child were BuV-DNA negative.
Figure 1. SDS-PAGE (a) and electron microscopy pictures (b) of VP2-VLPs of BuV1-3 and TuV.
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sampling. Consequently, the seroprevalence among the native Finnish subjects was 3.1% (5/163), whereas 5/12 
(41.7%) Asian subjects and 3/6 (50%) Indian subjects were seropositive. All BuV IgG-positive adults of Finnish 
background had low OD values.
Follow-up samples were available from five BuV IgG-positive adults, including all four with high OD values. 
The samples were analysed with BuV-IgG EIA, and the OD values, which reflect the antibody titres in the tested 
subjects, were shown to remain stable for up to six years (Table 2).
Bufavirus and tusavirus IgG in children. Among the 228 children studied for BuV and TuV IgG anti-
bodies, seven (3.1%) had BuV IgG and one (0.4%) had TuV IgG. Of the BuV IgG-positive cases, one had IgG for 
BuV1, three for BuV2, two for BuV3 and one for both BuV1 and 2 (Fig. 2). The BuV-seropositive children were 
between 7 months and 5 years of age at the time of sampling, whereas the TuV-seropositive child was 9 years of 
age.
In addition to the true BuV or TuV seropositive samples, we encountered four children with low BuV IgG 
OD values with indeterminate blocking results (one BuV1 and three BuV2). These results were interpreted as 
negative.
Among the BuV DNA-positive cases, a serum sample was available only from the nasal swab-positive child. 
The serum was both BuV-DNA and BuV-IgG negative for all BuV types pointing either to a superficial or local 
respiratory tract infection without viremia or antibody responses or to a very early acute systemic infection still 
Geographical 
background Sampling date
Absorbance value (OD) without competition
BuV1 IgG BuV2 IgG BuV3 IgG TuV IgG H5 IgG
Case 1 Middle-East 4.3.2010 2.742 2.793 2.827 0.030 0.040
24.9.2010 2.657 2.958 2.958 0.028 0.042
22.12.2010 2.880 3.209 3.482 0.026 0.035
19.7.2011 2.437 2.666 2.576 0.027 0.032
18.2.2016 2.683 2.419 2.675 0.033 0.046
Case 2 India 6.1.2011 2.977 0.032 0.054 0.026 0.036
19.7.2011 2.900 0.039 0.056 0.028 0.038
Case 3 India 10.3.2010 3.642 0.040 0.061 0.041 0.037
6.1.2011 4.071 0.025 0.046 0.029 0.024
Case 4 India 11.3.2010 1.924* 0.454* 0.164* 0.079 0.496*
9.4.2010 2.330* 0.534* 0.228* 0.096 0.616*
Case 5 Finland 19.10.2009 0.248 0.069 0.022 0.020 0.050
1.11.2011 0.258 0.084 0.028 0.020 0.055
21.1.2014 0.271 0.091 0.027 0.024 0.057
17.2.2016 0.295 0.126# 0.034 0.029 0.076
Table 2.  Bufavirus IgG-positive adults with follow-up samples. The positives are indicated with bolded 
numbers. H5 = High5 insect cells. *BuV2, BuV3 and H5 reactivity was completely blocked in competition assay 
by insect cell suspension, but not with the specific BuV VLP. The BuV1 result was blocked only with BuV1. See 
also Table 3. #BuV2 reactivity was blocked with insect cell suspension, not by BuV2 VLP.
Blocking VLP/
suspension
Case 1, sample taken 
4.3.2010
Case 4*, sample taken 
11.3.2010 Case 13 Case 16 Case 18







BuV1 BuV2 BuV3 BuV1 BuV2 BuV3 BuV2 BuV3 TuV
none 2.588 2.761 2.896 2.011 0.644 0.174 0.156 0.142 0.314
BuV1 0.030 2.587 2.661 0.127 0.458 0.132 0.177 0.107 0.299
BuV2 2.579 0.038 2.722 1.949 0.167 0.143 0.023 0.111 0.191
BuV3 2.400 2.614 0.080 1.904 0.472 0.151 0.191 0.024 0.377
TuV 2.513 2.720 2.819 1.997 0.525 0.172 0.164 0.116 0.101§
High5 insect 
cells 2.638 2.845 2.954 2.016 0.074
# 0.087# 0.211 0.116 0.401
Table 3.  Examples of competition assay results. Specific blocking is demonstrated with bolded numbers. 
*Case 4 is strongly IgG positive for both BuV1 and insect cells (also seen in Table 2). BuV2 and BuV3 VLPs have 
been shown to have insect cells impurities (data not shown), which causes more reactivity towards BuV2 and 
BuV3 antigens. This reactivity is completely blocked by insect cell suspension (marked with#), and the sample 
is therefore considered to be IgG positive only for BuV1 among the tested viral antigens. The blocking effect of 
BuV2 VLP towards BuV2 is interpreted to be caused by the insect cell impurities rather that the VLP itself. §5x 
more blocking antigen was used to block the IgG reactivity.
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awaiting an immune response. Although this 20-month-old child had been hospitalized for four days and had 
underlying health issues including operated cleft palate, heart problems and asthma, a serologically confirmed 
acute HBoV2 infection suggests that this child was B-cell immunocompetent18.
Specificity of bufavirus and tusavirus B-cell immunity. In order to ensure that the EIA absorbance 
values were specific for the particular virus, i.e. not due to cross-reactivity with known similar viruses or unspe-
cific reactions, all samples with a measurable OD value of ≥0.1 underwent confirmatory competition assays by 
blocking with soluble VLPs and insect cell lysate. Samples with OD values below 0.1 were too difficult to unam-
biguously confirm by blocking and were thus considered negative. Of note, the determination of an exact cutoff 
value was not crucial for the interpretation of the results as all samples with OD values of ≥ 0.1 were confirmed by 
competition assay and only the confirmed results were considered genuinely positive.
The antibodies in all BuV- or TuV-seropositive samples showed no cross-reactivity between the BuV geno-
types or TuV, including the triple-BuV seropositive plasma (Case 1; Table 3). Both in a high-positive adult (Case 1) 
and in a low-positive adult (Case 5), we could show that the BuV antibody levels and specificity remained con-
stant for at least six years (Table 2). Furthermore, among the 84 medical students, the BuV1-3 and TuV IgG EIA 
results correlated neither with each other nor with the previously analysed IgG EIA results of six other human 
parvoviruses: HBoV1-4, PARV4, or parvovirus B19 (data not shown)19–21.
Notably, some of the sera did contain antibodies toward High5 insect cells in which our antigens were 
expressed: 9/180 (5.0%) in the adult cohort with ODs of 0.104–0.616, and 13/228 (5.7%) in the paediatric cohort 
with ODs of 0.096–0.404. Some of these High5 backgrounds would have yielded incorrect positivity in the 
unblocked BuV IgG EIAs, more with BuV2 and 3 than BuV1 or TuV antigens. However, we were able to dis-
tinguish false from genuine reactivity by competing with insect cell lysate, as can be seen in patient number 4 
(Tables 2 and 3): the BuV2 and BuV3 reactivities were completely blocked in the competition assay by insect 
cells, but less or not at all by VLPs of either of these two BuVs, whereas the BuV1 result was blocked with the 
homologous BuV1 (Table 3). In our previous studies we have seen the same phenomenon with Sf9 insect cells. 
Human antibodies towards insect cell components should therefore be considered when applying in EIA insect 
cell-derived antigens.
Discussion
Bufavirus and tusavirus are among the newest parvoviruses discovered in humans by deep sequencing1,2. Until 
now, human bufaviruses, mostly BuV1 or BuV3, has been detected by PCR in several geographical locations in 
Africa, Europe and Asia; but exclusively in diarrheal stools1,5,7–11. Studies have not included other sample types 
or other diagnostic means, yet the closely related BuV-like viruses have been found in spleens or sera of infected 
animals, indicating systemic infections12,13. Here we analysed for BuV DNA, stool samples and nasal swabs; as 
Figure 2. BuV and TuV IgG-positive adults and children. The figure presents the EIA OD values from the 
samples. Blue x marks the BuV1 IgG level in the sample, red circle the BuV2 IgG level, green diamond the BuV3 
IgG level and the black square the TuV IgG level. Below each result the following information is presented: 
Age, gender, geographical background (M-E = Middle-East, IND = India, CHN = China, FIN = Finland), case 
number and cohort.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:39267 | DOI: 10.1038/srep39267
well as for BuV and TuV antibodies, sera of children with respiratory infection, gastroenteritis or both. We also 
determined the corresponding seroprevalences among asymptomatic adults.
In the stool samples, we found a low BuV-DNA prevalence in Finnish children presenting with acute gas-
troenteritis with or without respiratory tract infection, in line with prior reports1,5,9–11. We observed for the first 
time BuV DNA in a nasal swab, albeit at a very low quantity, and with no BuV IgG nor DNA detectable in a cor-
responding serum. In each child with BuV DNA in stool, a known gastrointestinal virus was identified, possibly 
accounting for the illness. However, none of the 545 children without gastroenteritis had BuV DNA in stool, 
suggesting BuV could be a contributing factor to the disease.
Human parvovirus VLPs can be constructed using solely the major capsid protein, and such VLPs are often 
the antigens of choice in serodiagnosis19,22–27. In this study we showed that the VP2 proteins of all three BuV gen-
otypes and TuV are capable of assembling into VLPs, as with other human parvoviruses, and used these VLPs in 
EIAs for BuV and TuV serology.
The highest BuV IgG prevalence was detected among Asian asymptomatic adults; however, without statistical 
power due to low sample number. Of the Asian subjects 5/12 were positive, and the highest number was observed 
among Indian persons of whom 3/6 were BuV-IgG positive. These individuals had also the highest BuV IgG OD 
values, unlike the children or adults of Finnish descent. In addition, the prevalence of BuV antibodies in Finnish 
children (3.1%, 7/228) was identical to that in the native Finnish adults (3.1%, 5/163) raising the question why the 
BuV IgG prevalence did not increase with age. Although we did show that the antibody levels among adults can 
remain constant for at least six years, waning of the antibodies over time might play a role. Furthermore, if the 
primary infection of the host is local and superficial, it might not induce a strong long-lasting antibody response. 
With HBoVs it has been shown that exposure to homo- or heterologous HBoV species may boost the antibody 
response28,29. Thus, the similar BuV seroprevalence among Finnish adults and children might be a consequence 
of the general rarity of BuV infections in the Nordic countries, leading to inadequate maintenance of antibody 
responses.
In our previous study of stools of Finnish children and adults during 2012–2013, we detected BuV DNA 
exclusively of genotype 17. In the present study we found six children with antibodies to genotypes 2 or 3, while 
only two had antibodies to genotype 1 (of note, one child had both BuV1 IgG and BuV2 IgG). These BuV2 or 
3 IgG-positive children were 7 months to 5 years of age at the time of sampling (2009 to 2011), suggesting that 
BuV2 and maybe BuV3 might have circulated in Finland between 2006 and 2011. Unfortunately, we do not 
have travel information of these children. The BuV3 antibodies in the two 7- to 8-month-old infants might be 
maternal. It is interesting that in both of our cohorts BuV2 IgG was the most frequent, while BuV2 DNA has been 
detected in only a single patient, in the original publication1.
Most of the human parvoviruses have several variants or genotypes. This is the case also for BuV. The vari-
ants of human parvovirus B19 (B19V) differ in VP2 aa sequence by only 1–2%30,31, and cross-react fully in EIA. 
Therefore, B19V serodiagnosis can be done reliably using as antigen VP2 VLPs of any of the variants32–34. On the 
other hand, the more divergent four HBoVs (with a 11–23% difference in the major capsid protein aa sequence) 
are partly cross-reactive in EIA19. The cross-reactivity can be visualized by blocking the serum with heterologous 
HBoVs prior to the EIA. To identify such cross-reactivity is a prerequisite for correct interpretation of the HBoV 
EIA results19,29. The human bufavirus genotypes differ by 27–36% in VP24, and in our EIA analysis the BuV 
genotypes were not cross-reactive. Neither the BuV genotype, the antibody level in the sample, nor the age of the 
subject affected assay specificity. Interestingly, we found one adult and one child with specific antibodies towards 
more than one BuV type (case 1 with a triple and case 7 with a double positivity, shown in Fig. 2). In conclusion, 
we showed the three BuV genotypes also to represent three diverse serotypes.
We analysed the serum IgG reactivities against a number of factors known to cause background in EIA, 
including insect cell lysate, non-antigen-coated microwells and streptavidin. Of both adults and children 5–6% 
had antibodies towards insect cell constituents, which would cause false positivity without competition assays. 
Such false reactions should be considered when applying insect-cell produced antigens in EIA.
This is the first published human study of TuV since the initial article. While we found a single child to exhibit 
TuV IgG, in confirmatory blocking a 5-fold higher concentration of the homologous antigen was required than 
in the corresponding BuV EIAs, to block the IgG binding. As none of the other antigens (BuV1-3) or insect 
cell lysate blocked the TuV IgG reactivity, the result was considered TuV specific. More studies are nevertheless 
needed to confirm whether TuV actually is a human virus.
Taken together, we observed for the first time BuV DNA, aside from pediatric stools, in a nasal swab. More 
importantly, this is the first study documenting the presence of BuV and TuV IgG antibodies in humans. We 
furthermore showed that the three bufaviruses represent different serotypes: none of the BuVs nor TuV were 
mutually cross-reactive in the cohorts studied. While in Finland the seroprevalences of both of these protoparvo-
viruses were low, we observed both higher OD values and a higher seroprevalence of BuV among persons with 
an Asian origin, indicating that BuV infections might be more common in other countries, particularly in India. 
The BuV-specific immune responses of all three serotypes appeared to be strong and lasting, pointing to systemic 
infections. Overall, our results together with those of others indicate that BuV is a human virus, whereas addi-
tional studies are needed to assess the host tropism of TuV and the clinical correlates and global epidemiology of 
these viruses as well as their transmission route(s).
Materials and Methods
Patients and Samples. The adult cohort consisted of serum or plasma samples from 180 healthy adult vol-
unteers: 84 medical students from the University of Helsinki and 96 staff members from the Helsinki University 
Hospital or from the Faculty of Medicine, University of Helsinki (median age 30 years, range 19–65). A written 
informed consent was obtained from all subjects, and the samples were collected between 2007 and 2013. All 
medical students and 79/96 of the staff were of Finnish descent, the remaining 17 staff members were originally 
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from Asia (12), the Americas (1) or other European countries (4). Follow-up samples were collected from BuV 
IgG-positive participants, or obtained (frozen-stored) from our archive. The Ethics Committee of Helsinki and 
Uusimaa Hospital District approved the study protocol, and the study was conducted in accordance with the 
relevant guidelines and regulations.
The samples and clinical information of the paediatric cohort have been described previously18. Shortly, the 
patients (n = 955) were recruited between September 2009 and August 2011 in Tampere, Finland, and the sam-
ples were collected throughout the year. The children were divided in three groups based on signs and symp-
toms: acute gastroenteritis (AGE, n = 172), acute respiratory tract infection (ARTI, n = 545) or symptoms of both 
(n = 238). The median age was 14 months (range 6 days – 15.6 years). There were patients both from a paediatric 
outpatient clinic, 137 (14.3%), and a hospital ward, 818 (85.7%). Stool and nasal swab samples were available 
from every child and serum samples were from 228 children of whom blood sampling was medically indicated. A 
written informed consent was obtained from the parents of all the children enrolled. The study was approved by 
the Ethics Committee of Pirkanmaa Hospital District, and, and the study was conducted in accordance with the 
relevant guidelines and regulations.
DNA extraction and bufavirus quantitative PCR. DNA was extracted from stool and nasal swab 
samples as described in Paloniemi et al., and the DNA aliquots were analysed with BuV-qPCR as described in 
Väisänen et al.7,18. In qPCR-positive cases the amplicon was sequenced to confirm the result; however, the nearly 
identical sequence in the NS1 amplicon area prevented BuV genotyping.
Generation of recombinant BuV1-3- and TuV-VP2 baculoviruses. Recombinant baculoviruses were 
created with the Bac-to-Bac Baculovirus Expression System (Invitrogen) according to the manufacturer’s instruc-
tions. Briefly, DNA was extracted from the original BuV and TuV DNA-positive stool samples (BuV1 and 21, 
BuV35 and TuV2) with the QIAamp DNA mini kit (Qiagen, Germany). The putative VP2 gene was amplified with 
Phusion High-Fidelity DNA Polymerase (Thermo Fischer Scientific) by using primers with designed BamHI and 
SalI restriction sites (Table 4). The amplicon was introduced into the pFastBacDual vector (Invitrogen) by the 
restriction sites, and the generation of recombinant BuV1-3- and TuV-VP2 bacmids and the subsequent trans-
fection into Spodoptera frugiperda Sf9 insect cells were performed according to the manufacturer’s instructions. 
The resulting virus from each transfection was amplified in three consecutive passages in Trichoplusia ni High5 
insect cells.
BuV1-3- and TuV-VP2-VLP expression and purification. For protein expression and VLP produc-
tion, High5 insect cells were infected with the recombinant baculovirus and grown for 5 days at + 27 °C. The 
cells were collected by centrifugation (4300 g, 5 min) and re-suspended in 20 mM Tris-HCl, pH 8.0, containing 
Complete-EDTA-free protease inhibitor cocktail (Roche), and were frozen-stored at − 20 °C.
The cell suspension was treated with 0.5% sodium deoxycholate (Sigma-Aldrich) for 30 min at + 37 °C 
with 600 rpm shaking, chilled on ice, and sonicated 8 × 10 sec with 50% amplitude. The lysate was centrifuged 
at 16100 g for 30 min at + 4 °C. The supernatant was collected and the remaining pellet was re-suspended, 
re-sonicated and re-centrifuged. The precleared lysates from the two sonication rounds were combined and 
loaded onto a CsCl double cushion with densities of 1.52 g/cm3 and 1.22 g/cm3 in 10 mM Tris-HCl (pH 7.8) 
containing 1 mM EDTA. Ultracentrifugation was performed at 65 000 g for 4 h at 10 °C. Fractions were collected 
and subjected to SDS-PAGE and the VLP fraction(s) were dialyzed 3 times against PBS. The final purified and 
dialyzed VLPs were viewed under electron microscopy (Fig. 1).
BuV and TuV VP2-VLP IgG EIA assays. Various plastics and buffers as well as VLP, antibody and sub-
strate concentrations were systematically compared, and the following protocol was chosen. The purified VP2 
VLPs were biotinylated using the EZ-Link Sulfo-NHS-LC-Biotin kit (Thermo Fischer Scientific) according to the 
manufacturer’s instructions, and the biotinylated VLPs were used as antigens in EIA. Sonicated High5 insect cells 
were biotinylated as well, and used as control antigen. The biotinylated VLPs or insect cell lysate (80 ng per well in 
PBS containing 0.05% Tween 20 [PBST]) were immobilized on streptavidin-coated plates (UniverSA96-Lockwell, 
Kaivogen) for 1 hour at room temperature with 400 rpm shaking. To minimize non-specific background, the 
plates were post-coated 3 × 10 min with the Diluent (Labsystems Diagnostics). Plasma or serum samples were 
diluted 1:200 in RED buffer (Kaivogen) and incubated for 1 hour at room temperature with 400 rpm shaking. 
Primer Sequence
BuV1 VP2 fwd BamHI TAggatccATGACTGACACACAAGATGTATCTGA
BuV1 VP2 rev SalI ATTgtcgacTCCATTTTAGATTGTGTAGTTAGGCATAC
BuV2 VP2 fwd BamHI TAggatccATGTCTGAAAGCAATGAAATTGGAG
BuV2 VP2 rev SalI ATTgtcgacTTACATTGTGTAGTTAGGCATGGCTCT
BuV3 VP2 fwd BamHI TAggatccATGTCCGAAAGCAATGAAATTGACG
BuV3 VP2 rev SalI ATTgtcgacTTAGTATGTGTAGTTTGGCATTGCTC
TuV VP2 fwd BamHI TAggatccATGGCAGCCTCTAGCTCAGACAGTG
TuV VP2 rev SalI ATTgtcgacTTAGTAAACAGTAGAGGGTACAATTCTTC
Table 4.  Primers used for amplifying the VP2 gene of BuV1, 2 and 3 and TuV. The restriction sites are 
written in lower case.
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Wells were washed 4 times with PBST and horseradish-peroxidase conjugated anti-human IgG (DAKO), diluted 
1:4000 in the Diluent, was applied for 1 hour. After 4x PBST washes, 3,3′ ,5,5′ -tetramethylbenzidine (TMB, 
DAKO) was applied for 10 min, the reaction was stopped with 0.5 M H2SO4, and the ODs were measured at 
450 nm (Multiskan EX, Thermo Fischer Scientific). Blank ODs were subtracted from the test ODs.
IgG testing of human sera. IgG EIA analyses for BuV1, BuV2, BuV3 and TuV as well as for High5 insect 
cells were carried out in panels, in which each sample was analysed for all five antigens simultaneously in adja-
cent wells (one well per antigen). This procedure would reveal any unspecific background due to various factors, 
allowing their assessment in more detail. To confirm the IgG results and determine the antigenic cross-reactivity 
of BuV1-3 and TuV, all samples showing measurable OD values (≥ 0.1) were subjected to homologous and het-
erologous competition, as described for human bocaviruses19. In brief, the plasma or serum sample was mixed 
with an unbiotinylated antigen (VP2-VLP at 20 μ g/ml or High5 insect cell lysate at 0.5 mg/ml) prior to the EIA 
of interest. Each reactive sample was separately blocked both with the homologous antigen, which should fully 
block a specific reaction, and with all four heterologous antigens, which should not block the specific reaction. 
The overall BuV-IgG result after competition was considered positive when no heterologous blocking occurred 
and the residual OD fell upon homologous blocking (i) below OD 0.2, when the non-blocked OD was > 0.5; (ii) 
below OD 0.15, when the non-blocked OD was 0.3–0.5; and (iii) below 50% of the non-blocked OD, when the 
non-blocked ODs were low, 0.1–0.3. Examples of blocking results are shown in Table 3. For effective blocking 
in TuV EIA, a 5-fold higher concentration of homologous blocking antigen, compared to that in BuV EIA, was 
required (Case 18, Table 3).
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